117 results about "RANKL" patented technology

Devices and methods for stimulation of the vagus nerve to modulate (e.g., reduce, suppress, etc.) bone erosion. Methods and apparatus for modulating bone erosion may modulate levels of Receptor Activator for Nuclear Factor κ B Ligand (RANKL), and / or to modulate (increase, enhance, etc.) osteoprotegerin (OPG) and / or OPG / RANKL ratio. Devices may include electrical stimulation devices that may be implanted, and may be activated to apply current for a proscribed duration, followed by a period without stimulation.

A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL / TRANCE, with collecting, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collectin fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members.

Novel methods and drug products for treating inflammatory joint diseases such as rheumatoid arthritis and associated arthritides are disclosed. The methods and products employ various serum markers of bone and cartilage metabolism or destruction, including cartilage oligomer matrix protein (COMP) and Receptor activator of NFB ligand (RANKL), as biomarkers to assess the effect of IL-17A antagonists on joint destruction in inflammatory joint diseases.

The invention relates to methods and compositions for inhibiting the trimerization of ligands belonging to the TNF superfamily. In particular, the invention relates to inhibiting RANKL trimerization. Accordingly, the methods and compositions provided herein can be used to treat disorders associated with increased RANK signalling, in particular those related to bone loss. Novel compounds that inhibit trimerization of ligands belonging to the TNF superfamily are also provided.

The invention provides an antibody pair for detecting RANKL content in serum and application thereof. According to the invention, RANKL antigen is divided into two sequences of N end (SEQ ID NO: 2) and C end (SEQ ID NO: 3), and the two sequences are respectively used for immunizing mice to screen antibody pairs anti AntiRANKL_N and anti AntiRANKL_C with high specificity and high sensitivity. The antibody pair can effectively determine RANKL content in serum, and is convenient for diagnosis and treatment of osteoporosis.